Welltower is in a sustained, powerful uptrend, with the shares up 29.75% over the trailing twelve months versus a 15.01% gain for the S&P 500, delivering 14.74 percentage points of relative strength. At a current price of $227.71, the stock sits at approximately 70% of its 52-week range (52-week low of $163.75, 52-week high of $255.20), meaning it has surrendered meaningful ground from its July peak but remains far above its lows — a positioning that suggests a healthy consolidation within a bull trend rather than a broken chart. The 21.81% year-to-date gain confirms that buyers have controlled the tape for most of 2026, though the failure to hold the $255 area signals that momentum has cooled at the margin.

Short-term momentum has clearly decelerated and now diverges from the longer-term trend: the stock is down 4.56% over the past month and 3.54% over the past three months, even as the 1-year return remains strongly positive at 29.75%. This divergence is corroborated by relative strength figures — WELL has underperformed SPY by 5.15 percentage points over the past month and by 6.88 points over three months, a notable reversal from its 8.95-point YTD outperformance. The 6-month change of +12.54% versus SPY's +17.35% (relative strength of -4.81) indicates the stock's leadership faded after the spring, and the recent drift from $241 in late August to $227.71 today looks like a controlled pullback or mean-reversion phase rather than an outright trend reversal, especially given the modest +0.34% bounce on the most recent session.

Key technical levels are well defined: support rests at the 52-week low of $163.75, with a more immediate psychological floor around the $220–$225 zone where the stock has stabilized in late September and early October, while resistance sits at the 52-week high of $255.20. A decisive breakout above $255 would reassert the primary uptrend and likely target new all-time highs, whereas a breakdown below $220 would open the door to a deeper retracement toward the $200 area and potentially the 52-week low. Volatility is modest relative to the market — beta of 0.76 means the stock is roughly 24% less volatile than SPY, which supports smaller position-sizing adjustments for risk management and helps explain the orderly nature of the recent pullback; the maximum drawdown of -12.61% over the period is consistent with a low-beta, income-oriented REIT profile rather than a high-octane growth name.

Welltower's revenue trajectory is one of aggressive expansion: Q2 2026 revenue reached $3.545 billion, up 40.87% year-over-year from $2.516 billion in Q2 2025, capping a multi-quarter sequence of $2.388B (Q1 2025), $2.516B (Q2 2025), $2.628B (Q3 2025), $3.134B (Q4 2025), $3.306B (Q1 2026), and $3.545B (Q2 2026) that shows accelerating sequential growth rather than deceleration. The growth engine is overwhelmingly the senior housing operating portfolio: resident fees and services contributed $2.985 billion of the quarter's revenue, versus $459.7 million from rental income, $77.4 million from interest income, and $22.6 million from other income — meaning the resident-fee segment accounts for roughly 84% of total revenue and is the primary driver of both growth and operational risk. This acquisition-fueled expansion (Q2 alone saw $5.2 billion of acquisitions net of dispositions) strengthens the investment case around demographic demand for senior housing, but it also means reported growth is heavily inorganic and dependent on continued access to capital markets.

Profitability is positive but thin relative to the scale of the asset base: Q2 2026 net income was $240.3 million on $3.545 billion of revenue, a net margin of just 6.78%, while gross margin stood at 39.34% and operating margin at 16.62%. The quarterly earnings pattern is volatile — Q1 2026 net income of $728.7 million (22.0% net margin, boosted by $205.5 million of other income) contrasts sharply with Q4 2025's $96.4 million and negative EBITDA of -$459.4 million, which was distorted by a $1.557 billion SG&A charge and a $1.057 billion other-expense line. Gross margin has been remarkably stable in the 38–40% band across every quarter from Q1 2025 through Q2 2026 (39.34%, 37.82%, 38.30%, 39.99%, 39.80%, 38.78%), indicating that core property-level economics are consistent and that earnings volatility stems from below-the-line items, depreciation, and transaction activity rather than margin compression. For a healthcare REIT, a ~39% gross margin and mid-single-digit net margin are typical given the capital-intensive, depreciation-heavy nature of the model, and the key profitability metric for investors is really EBITDA and FFO rather than GAAP net income.

The balance sheet is solid but increasingly leveraged by acquisition activity: debt-to-equity is 0.507, total debt to capitalization is 29.8%, and the current ratio is a robust 5.34, reflecting $2.10 billion of cash at the end of Q2 2026 against modest short-term obligations. Free cash flow remains healthy — $881.2 million in Q2 2026 and $2.662 billion on a trailing twelve-month basis — but the company is clearly funding growth externally, having issued $2.907 billion of common stock in Q2 2026 alone and $1.545 billion in Q1, while paying $524.4 million of dividends in the quarter. ROE of just 2.22% and ROA of 0.83% look weak on the surface, but for a REIT these figures are depressed by massive depreciation and the lag between capital deployment and stabilized yields; the more telling metrics are the dividend payout ratio of 200% of GAAP earnings (unsustainable on a GAAP basis but normal for REITs measured on FFO/AFFO) and the dividend yield of 1.52%, which is low for the sector and signals the market is pricing WELL as a growth REIT rather than an income vehicle.